Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis

Hiroyuki Ando, Kunihiro Suzuki, Toyoshi Yanagihara

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)

Abstract

Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death-1-ligand 1 (PD-L1) have become new treatment options for various malignancies. ICIs bind to immune-checkpoint inhibitory receptors or to the foregoing ligands and block inhibitory signals to release the brakes on the immune system, thereby enhancing immune anti-tumor responses. On the other hand, unlike conventional chemotherapies, ICIs can cause specific side effects, called immune-related adverse events (irAEs). These toxicities may affect various organs, including the lungs. ICI-related pneumonitis (ICI-pneumonitis) is not the most frequent adverse event, but it is serious and can be fatal. In this review, we summarize recent findings regarding ICI-pneumonitis, with a focus on potential pathogenesis and treatment.

Original languageEnglish
Article number1484
JournalBiomedicines
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2021

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • General Biochemistry,Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis'. Together they form a unique fingerprint.

Cite this